Menu
Recruiting NCT02745158

The Fibrodysplasia Ossificans Progressiva (FOP) Registry

Observational Fibrodysplasia Ossificans Progressiva (FOP)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Fibrodysplasia Ossificans Progressiva (FOP). Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

FOP Registry: A Global Registry for the Fibrodysplasia Ossificans Progressiva Community

Overview

The Fibrodysplasia Ossificans Progressiva (FOP) Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. A physician portal (in development) will allow physicians to enter clinical data about their patients. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.

Detailed description

The FOP Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based patient portal. No experimental intervention is involved. The objectives are to organize the international FOP community for participation in clinical trials; to enable FOP patients worldwide to report data in a shared forum; to improve the collective understanding of FOP natural history; and to advance the understanding of FOP treatment outcomes.

The Registry collects data through two sources. First, the Patient Portal (launched in July 2015) allows FOP patients and caregivers to enter information about their experiences living with FOP. Second, the Physician Portal (in development) will allow physicians to enter clinical data about patients under their care. The Registry will be capable of including data on specific marketed therapies under the direction and control of a sponsoring pharmaceutical company. Key identifiers will link the physician-reported data with the Patient Portal data.

Participants must have a confirmed diagnosis of FOP and the participant (or a parent or legal guardian) must be willing and able to provide written informed consent. There are no exclusion criteria. Data collected in the Patient Portal include: patient demographics and diagnosis pathway; medical and dental care; clinical research participation and biospecimen donation; heterotopic ossification (bone growth and episodic flare-ups); other signs and symptoms by body system; patient-reported outcomes (physical functioning, pain, fatigue, and general health); and assistive devices, aids, attendants, and adaptations. Because the Registry is designed to accommodate participants along a broad spectrum of FOP disease severity, most of the data fields are optional, allowing participants a high degree of flexibility in how much information they contribute, which also minimizes participant burden.

After completing the informed consent, participants enter their baseline (historical) data. Participants will be encouraged to update their information at least twice per year. Participants may withdraw their consent at any time without prejudice or providing an explanation. The Registry has no pre-specified end date and will continue for as long as it is sustainable and useful to the FOP community.

Primary outcome measures

  • Patient Reported Changes in New Bone Growth Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Episodic Flare-Ups Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Mobility Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
Secondary outcome measures (9)
  • Patient Reported Changes in Health Resource Utilization Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Ear Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Skin Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Central Nervous System Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Pulmonary System Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Gastrointestinal System Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Cardiovascular System Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Renal System Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]
  • Patient Reported Changes in Signs Related to the Endocrine System Using a Patient-Directed Survey Developed by the IFOPA [Time frame: Baseline, then every six months for up to 10 years]

Eligibility criteria

Inclusion criteria

  • Participants must have a confirmed diagnosis of FOP.
  • Participants (or a parent or legal guardian) must be willing and able to provide written informed consent.

Exclusion criteria

  • There are no exclusion criteria.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

United States · 1 center
  • The International Fibrodysplasia Ossificans Progressiva Association (IFOPA) — North Kansas City

Publications

  • Pignolo RJ, Kimel M, Whalen J, Kawata AK, Artyomenko A, Kaplan FS. The Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ): A patient-reported, disease-specific measure. Bone. 2023 Mar;168:116642. doi: 10.1016/j.bone.2022.116642. Epub 2022 Dec 13. PMID 36526263

Identifiers

NCT: NCT02745158 · IFOPA-REG-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗